Skip to main content
. 2022 Mar 30;108(6):518–527. doi: 10.1111/ejh.13763

TABLE 1.

Demographic information

Total FVIII deficiency FIX deficiency
n 49 (100) 35 (71) 14 (29)
Age (years) 44 (32, 52) 39 (29, 50) 48 (33, 56)
Age groups
18–32 years 13 (26) 11 (85) 2 (15)
33–52 years 24 (49) 18 (75) 6 (25)
53–71 years 12 (25) 6 (50) 6 (50)
Severity
Severe 43 (88) 30 (70) 13 (30)
Moderate 6 (12) 5 (83) 1 (17)
Treatment history
Prophylaxis 43 (88) 30 (70) 13 (30)
On demand 6 (12) 5 (83) 1 (17)
Age prophylaxis commenced (years) a 26 (13, 49) 23 (12, 42) 41 (17, 52)
Age prophylaxis commenced by age group
<3 years 5 (13) 4 (80) 1 (20)
3–17 years 9 (24) 7 (78) 2 (22)
≥18 years 24 (63) 15 (63) 9 (37)
BMI (kg/m2) 27.0 (24.8, 29.6) 26.8 (24.1, 30.6) 28.0 (24.8, 29.2)
HJHS b
Total 28 (20, 36) 29 (20, 38) 24 (20, 35)
Left ankle 5 (2, 8) 5 (2, 7) 6 (4, 8)
Right ankle 7 (4, 8) 6 (4, 7) 7 (6, 9)
Left knee 1 (0, 5) 1 (0, 5) 1 (1, 7)
Right knee 1 (0, 3) 1 (0, 3) 1 (1, 4)
Left elbow 3 (0, 7) 4 (0, 7) 1 (0, 4)
Right elbow 4 (0, 8) 4 (0, 8) 4 (0, 9)
Global gait score 4 (4, 4) 4 (4, 4) 4 (4, 4)
HJHS by age category b
18–32 years 20 (4, 23) 21 (7, 26) 1 c
33–52 years 27 (21, 38) 31 (21, 41) 22 (18, 23)
53–71 years 34 (32, 46) 32 (32, 40) 35 (32, 53)
History of inhibitors
Inactive 6 (12) 5 (83) 1 (17)
No history 43 (88) 30 (70) 13 (30)

Data are presented as median (IQR‐ Q1, Q3); Categorical variables are presented as n (%).

Abbreviations: BMI, body mass index; HJHS, haemophilia joint health score.

a

n = 38 (FVIII = 26; FIX = 12, remaining did not answer).

b

n = 44 (no HJHS available for 5 participants with moderate haemophilia).

c

n = 1, thus raw value is reported.